Company Overview
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company dedicated to developing potent biologics designed to treat the tumor microenvironment. The firm leverages a conditional activation platform technology for oncology biologics research and development, which comprises its core strategic approach to therapeutic innovation. This entity functions within the Healthcare sector, specifically in the Biotechnology industry, where companies typically focus on long-term R&D cycles to bring novel treatments to market. The company's current scale is defined by a market capitalization of $916.59M, annual revenue of $76.20M, and an employee base of 69 individuals. These financial figures indicate that the company possesses a mid-sized market cap relative to large-cap pharmaceutical peers but maintains a lean operational structure with fewer than 100 employees. The revenue figure of $76.20M suggests a specialized product portfolio, while the small workforce implies a high degree of capital intensity reliant on external financing rather than large-scale operational staffing.
Financial Health
The company reported a revenue of $76.20M over the trailing twelve months, yet it posted a net income of $-20,370,000 and an EBITDA of $-18,188,000. The significant gap between the positive revenue of $76.20M and the substantial net loss reveals a cost structure dominated by high operating expenses, likely driven by research and development activities inherent to the biotechnology sector. Free cash flow stands at $-43,208,500, indicating that the company is burning cash at a rapid pace, which limits its immediate financial flexibility to fund operations without external capital raises. Despite the losses, the company holds $137.05M in cash against $4.24M in debt, creating a substantial liquidity buffer. The debt-to-equity ratio of 4.28 suggests a levered balance sheet structure, yet the massive cash reserve mitigates immediate default risk. The current ratio of 3.09 indicates strong short-term liquidity, as the company holds more than three times the current value of its liabilities in assets. Return on Equity is -35.2% and Return on Assets is -9.0%, metrics that reveal management is currently generating negative returns on the capital deployed, a common characteristic for early-stage biotechnology firms focused on product development rather than profitability.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is -9.15. The negative forward P/E implies that analysts or market models expect earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio is 7.29, which indicates that the market is pricing the company at a significant premium of over seven times its book value, reflecting high expectations for future asset appreciation or successful clinical outcomes. The price-to-sales ratio is 12.03, and the EV/EBITDA is -32.37; these alternative valuation metrics suggest that traditional earnings-based metrics are insufficient for assessing value, and investors are relying on revenue multiples or asset backing. The stock has traded between a 52-week high of $8.21 and a 52-week low of $0.40. Without a specific current price in the provided facts to calculate the exact percentage deviation, the trading range demonstrates extreme volatility, having expanded significantly from its yearly low. The beta value of 2.48 indicates that the stock's price volatility is more than double that of the broader market, suggesting high sensitivity to market swings and specific sector events.
Growth & Income
Revenue growth year-over-year is recorded at -98.3%, while earnings growth is N/A due to the absence of prior year positive earnings. The negative revenue growth indicates a contraction in sales, which may stem from the expiration of patents, loss of key product indications, or a decline in commercial adoption during this reporting period. Since the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders. Instead of paying dividends, the company retains its earnings, though currently negative, to reinvest into its research and development pipeline and operational growth. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, positioning the asset as a pure-play speculative biotechnology investment reliant on future commercial success.